Strides Pharma Science announced that the Board of Directors of the Company have approved an additional investment up to a maximum of US$ 40 million over a period of 24 months for a controlling stake in Stelis Biopharma (Stelis).
The proposed new investments will be a primary infusion into Stelis which will enable Stelis to achieve its objective of becoming a compelling global player in the biopharmaceutical space and also accelerate Strides' re-entry into sterile injectables business post the completion of the Company's non-compete period in December 2019.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
